1. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
- Author
-
Ozdemir O, Boran M, Gökçe V, Uzun Y, Koçak B, and Korkmaz S
- Subjects
- Diabetes Mellitus drug therapy, Drug Interactions, Drug Therapy, Combination, Electrocardiography, Fatal Outcome, Gemfibrozil therapeutic use, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hyperlipidemias drug therapy, Hypolipidemic Agents therapeutic use, Male, Middle Aged, Myocardial Ischemia drug therapy, Pyridines therapeutic use, Renal Dialysis, Renal Insufficiency therapy, Rhabdomyolysis complications, Rhabdomyolysis therapy, Gemfibrozil adverse effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Hypolipidemic Agents adverse effects, Pyridines adverse effects, Renal Insufficiency chemically induced, Rhabdomyolysis chemically induced
- Abstract
Gemfibrozil-statin combination therapy is a well-known risk factor for myopathy and rhabdomyolysis. Cerivastatin is a currently available statin with dual elimination; it is therefore expected to cause less drug-drug interaction. This case is the second reported case with severe rhabdomyolysis caused by cerivastatin-gemfibrozil combination. Moreover, in this case, the rhabdomyolysis was more severe and caused severe renal failure and death. The authors discuss how these drugs cause rhabdomyolysis and how rhabdomyolysis can cause renal failure.
- Published
- 2000